A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Sponsor: |
Southwest Oncology Group |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS3544 |
U.S. Govt. ID: |
NCT03939481 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to try to learn how certain risk factors, such as age, gender, pre-existing conditions, the type of treatment you get for your cancer, and the amount of cancer drugs in your body affect whether you develop the nerve disorder and how bad your symptoms will be. There will be about 1,000 people taking part in this study.
This study is closed
Investigator
Meghna Trivedi, MD
Do you have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer? |
Yes |
No |
Are you 18 years of age or older? |
Yes |
No |
Are you planning to start treatment with a taxane-based chemotherapy? |
Yes |
No |